2 Outstanding Dividend Stocks to Buy and Hold for 10 Years

Johnson & Johnson shares are up 28% year to date versus a 10% gain for the S&P 500, supported by Q2 sales growth of 6.6% to $25.3 billion and adjusted EPS growth of 4.7% to $2.90. The company has raised its dividend for 64 consecutive years and is advancing products including ICOTYDE and its Ottava robotic surgery platform, while moving closer to resolving talc litigation. Merck's Q2 revenue rose 5% to $16.6 billion, with Winrevair sales up 75% to $588 million and Capvaxive sales up 42% to $184 million, supporting its strategy to offset Keytruda's 2028 patent-expiry risk.

Analysis

JNJ's diversification warrants a lower earnings-risk premium than large-cap pharma peers, but its recent relative strength likely embeds much of the de-risking from litigation progress and near-term execution. The investable question is whether medical-device growth and robotics adoption can offset mature-drug pricing pressure sufficiently to sustain a premium multiple; Ottava is strategically relevant but unlikely to be a material P&L contributor for at least 2-3 years. Residual talc liabilities, rather than the headline settlement process, remain the key left-tail issue if courts reject the proposed structure or additional claimants opt out.

MRK faces a more binary 2027-29 earnings-reset debate. A subcutaneous Keytruda formulation may preserve physician workflow and patient adherence, but it does not automatically preserve economics: payer reimbursement, biosimilar litigation outcomes, and the degree of price erosion after loss of exclusivity determine the retained franchise value. New-product growth must accelerate from a small base to replace a very large immuno-oncology profit pool, making consensus estimates most vulnerable in the 12-24 months before the patent cliff rather than on the actual expiry date.

The non-obvious beneficiary of MRK's oncology succession plan is MRNA, whose valuation is highly sensitive to credible non-COVID commercial validation. However, development collaboration headlines alone are insufficient: durability, recurrence-free survival, safety, and commercialization economics will determine whether the program changes MRNA's cash-burn trajectory. This is a low-impact, promotional-style article rather than a standalone catalyst; avoid chasing either pharmaceutical name on it.

Key Decisions for Investors

• Initiate a 6-12 month relative-value position: long JNJ / short MRK in equal dollar amounts. The trade isolates JNJ's lower concentration and litigation-normalization path against MRK's approaching patent-cliff multiple risk; target 10-15% relative return. Exit if MRK raises 2028-29 revenue guidance through credible replacement-product traction or if JNJ discloses incremental material talc reserves.
• For long-only healthcare exposure, accumulate JNJ only on a 5-8% pullback rather than extending after relative outperformance. Require device-segment growth and pharma operating-margin stability at the next two earnings prints; a guidance cut or adverse talc ruling invalidates the defensive-compounder thesis.
• Treat MRNA as an event watch, not a core recommendation. Consider defined-risk calls only after full melanoma trial data establish durable benefit and clarify MRK/MRNA profit sharing; failure to show clinically meaningful durability or a widening cash-burn outlook would leave the stock dependent on optionality rather than fundamentals.
• Monitor MRK's Keytruda franchise net-price trends, Qlex uptake, and 2028 consensus EPS revisions over the next 1-3 quarters. A material downward revision cycle before replacement assets reach scale would support increasing the MRK underweight; stable net pricing and accelerated Winrevair/Capvaxive guidance would be the near-term reversal signal.